Decreased Risk of Parkinson's Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls.
Parkinson’s disease
Rheumatoid arthritis
anti-inflammatory
autoimmune disease
Journal
Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
9
3
2021
medline:
24
12
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
Rheumatoid arthritis (RA) and the genetic risk landscape of autoimmune disorders and Parkinson's disease (PD) overlap. Additionally, anti-inflammatory medications used to treat RA might influence PD risk. To use a population-based approach to determine if there is an association between pre-occurring rheumatoid arthritis (RA) and later-life risk of PD. The study population was 3.6 million residents of Sweden, who were alive during part or all of the follow-up period; 1997-2016. We obtained diagnoses from the national patient registry and identified 30,032 PD patients, 8,256 of whom each was matched to ten controls based on birth year, sex, birth location, and time of follow-up. We determined the risk reduction for PD in individuals previously diagnosed with RA. We also determined if the time (in relation to the index year) of the RA diagnosis influenced PD risk and repeated the analysis in a sex-stratified setting. Individuals with a previous diagnosis of RA had a decreased risk of later developing PD by 30-50% compared to individuals without an RA diagnosis. This relationship was strongest in our conservative analysis, where the first PD diagnosis occurred close to the earliest PD symptoms (odds ratio 0.47 (CI 95% 0.28-0.75, p = 0.0006); with the greatest risk reduction in females (odds ratio 0.40 (CI 95% 0,19-0.76, p = 0.002). Our findings provide evidence that individuals diagnosed with RA have a significantly lower risk of developing PD than the general population. Our data should be considered when developing or repurposing therapies aimed at modifying the course of PD.
Sections du résumé
BACKGROUND
Rheumatoid arthritis (RA) and the genetic risk landscape of autoimmune disorders and Parkinson's disease (PD) overlap. Additionally, anti-inflammatory medications used to treat RA might influence PD risk.
OBJECTIVE
To use a population-based approach to determine if there is an association between pre-occurring rheumatoid arthritis (RA) and later-life risk of PD.
METHODS
The study population was 3.6 million residents of Sweden, who were alive during part or all of the follow-up period; 1997-2016. We obtained diagnoses from the national patient registry and identified 30,032 PD patients, 8,256 of whom each was matched to ten controls based on birth year, sex, birth location, and time of follow-up. We determined the risk reduction for PD in individuals previously diagnosed with RA. We also determined if the time (in relation to the index year) of the RA diagnosis influenced PD risk and repeated the analysis in a sex-stratified setting.
RESULTS
Individuals with a previous diagnosis of RA had a decreased risk of later developing PD by 30-50% compared to individuals without an RA diagnosis. This relationship was strongest in our conservative analysis, where the first PD diagnosis occurred close to the earliest PD symptoms (odds ratio 0.47 (CI 95% 0.28-0.75, p = 0.0006); with the greatest risk reduction in females (odds ratio 0.40 (CI 95% 0,19-0.76, p = 0.002).
DISCUSSION
Our findings provide evidence that individuals diagnosed with RA have a significantly lower risk of developing PD than the general population. Our data should be considered when developing or repurposing therapies aimed at modifying the course of PD.
Identifiants
pubmed: 33682730
pii: JPD202418
doi: 10.3233/JPD-202418
pmc: PMC8150472
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-832Références
JAMA Neurol. 2017 Jul 1;74(7):780-792
pubmed: 28586827
Curr Rheumatol Rep. 2011 Oct;13(5):431-9
pubmed: 21785978
Curr Aging Sci. 2017;10(3):158-176
pubmed: 28302047
Mayo Clin Proc. 2016 Oct;91(10):1346-1353
pubmed: 27712633
Ann Med. 2018 Feb;50(1):83-90
pubmed: 29224375
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Mov Disord. 2019 Jun;34(6):801-811
pubmed: 31091353
Lancet Neurol. 2020 Feb;19(2):170-178
pubmed: 31521533
Appetite. 2006 Jan;46(1):97-9
pubmed: 16298019
J Parkinsons Dis. 2019;9(3):501-515
pubmed: 31282427
J Parkinsons Dis. 2020;10(4):1649-1656
pubmed: 32716321
Ann Neurol. 2002 Sep;52(3):276-84
pubmed: 12205639
Neuroepidemiology. 2012;38(3):186-93
pubmed: 22472568
Arthritis Care Res (Hoboken). 2019 Jul;71(7):914-924
pubmed: 30790475
NPJ Parkinsons Dis. 2018 Jul 10;4:21
pubmed: 30003140
J Viral Hepat. 2020 Nov;27(11):1171-1178
pubmed: 32558154
Ann Rheum Dis. 2011 Apr;70(4):624-9
pubmed: 21149495
J Neurosci. 2016 May 4;36(18):5144-59
pubmed: 27147665
Am J Epidemiol. 2002 Apr 15;155(8):732-8
pubmed: 11943691
Neurology. 2009 Nov 3;73(18):1462-8
pubmed: 19776374
Arch Neurol. 2003 Aug;60(8):1059-64
pubmed: 12925360
J Parkinsons Dis. 2019;9(s2):S331-S344
pubmed: 31609699
Ann Neurol. 2005 Dec;58(6):963-7
pubmed: 16240369
Neurodegener Dis. 2012;10(1-4):277-84
pubmed: 22205172
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
JAMA Neurol. 2018 Aug 1;75(8):939-946
pubmed: 29710331
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875
pubmed: 30009205
Ann Rheum Dis. 2010 Jan;69(1):70-81
pubmed: 19174392
Trends Neurosci. 2019 Jan;42(1):4-13
pubmed: 30342839
Mov Disord. 2019 Jan;34(1):58-66
pubmed: 30653734
Mov Disord. 2020 Oct;35(10):1755-1764
pubmed: 32662532
Pharmacoepidemiol Drug Saf. 2020 Aug;29(8):864-872
pubmed: 32410265
Mov Disord. 2021 Jan;36(1):16-24
pubmed: 32357266
Ann Neurol. 2001 Jul;50(1):56-63
pubmed: 11456310